Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus pembrolizumab versus pembrolizumab plus placebo in previously treated advanced NSCLC
2024-513405-31-00Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing CC-486 plus pembrolizumab with Pembrolizumab plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Dec 2015; status: completed.
02
Drugs
CC-486pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513405-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513405-31-00.